Status | Study |
Recruiting |
Study Name: Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Condition: Cryoglobulinemic Vasculitis (CV) Drug-induced Vasculitis Date: 2016-12-20 |
Recruiting |
Study Name: Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Condition: Asthma Date: 2016-12-11 Interventions: Drug: Benralizumab one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every |
Recruiting |
Study Name: VCRC Tissue Repository Condition: Aortitis Cutaneous Vasculitis Eosino Date: 2016-11-11 |
Not yet recruiting |
Study Name: Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Condition: Asthma Date: 2016-10-17 Interventions: Drug: Reslizumab All subjects will receive Reslizumab |
Recruiting |
Study Name: Eosinophilic Granulomatosis With Polyangiitis Cohort Condition: Churg-Strauss Syndrome Date: 2016-09-26 |
Recruiting |
Study Name: Rituximab in Eosinophilic Granulomatosis With Polyangiitis Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA) Date: 2016-05-20 Interventions: Drug: Rituximab 1 g intravenou |
Not yet recruiting |
Study Name: Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome Condition: Churg-Strauss Syndrome Date: 2016-03-14 Interventions: Biological: HPC cell infusion Administration of total lymp |
Recruiting |
Study Name: Vasculitis Pregnancy Registry Condition: Vasculitis Behcet's Disease CNS Vasculitis Date: 2015-10-26 Interventions: Other: Online questionnaires Women will be asked to complete questionnaires during their pregnancy and a |
Completed |
Study Name: The ANCA Vasculitis Questionnaire (AAV-PRO©) Condition: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) Date: 2015-07-15 Interventions: Other: Online questionnaire |
Completed |
Study Name: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Condition: Churg-Strauss Syndrome Date: 2013-12-19 Interventions: Biological: Mepolizumab Mepoli |